Skip to content

Narrow Band Imaging (NBI) Under Electronic Bronchoscope in Lung Cancer

Application of Narrow Band Imaging (NBI) Under Electronic Bronchoscope in the Diagnosis and Staging of Lung Cancer

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04676815
Enrollment
200
Registered
2020-12-21
Start date
2023-06-30
Completion date
2024-07-31
Last updated
2023-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer, Malignant Airway Obstruction

Brief summary

Narrow-Band Imaging (NBI) is useful to better demarcate the superficial extent of central type of lung cancer, but its sensitivity and specificity in clinical practice were little studied. This study aimed to investigate the diagnostic effects of NBI in suspected patients with central lung cancer and its application in staging diagnosis of central lung cancer.

Detailed description

With high morbidity and mortality, lung cancer is one of the most common tumors in the world. Therefore, early detection, accurate diagnosis and staging division can effectively guide clinical interventions, thereby improving patient survival. Narrowband imaging under electronic bronchoscope (NBI) is an emerging optical image emphasis technology that can enhance the contrast between the mucosal surface and underlying blood vessels, specifically display the distribution of blood vessels, and highlight the subtle changes in mucosal structure. Meanwhile, it can reduce unnecessary biopsy with low risk and costs. In recent years, NBI technology has gradually begun to show its unique advantages in the diagnosis of gastric cancer, esophageal cancer, nasopharyngeal cancer, and bladder cancer. The purpose of this study is to explore the diagnostic value of NBI under electronic bronchoscopy for early detection and accurate diagnosis of lung cancer, and to provide a more economical, safer and more efficient diagnosis option for lung cancer patients.

Interventions

PROCEDURENBI and interventional bronchoscopy

NBI used to enhance the contrast between the mucosal surface and underlying blood vessels

Sponsors

Shanghai Pulmonary Hospital, Shanghai, China
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

\- Patients had a history or current central lung cancer

Exclusion criteria

\- NONE

Design outcomes

Primary

MeasureTime frameDescription
The specificity of diagnosis of NBI plus electronic bronchoscopy in central type lung cancer4 monthsAbnormal blood vessels or lack of staining is defined as suspected lesions. All the suspected lesions were biopsied.

Secondary

MeasureTime frameDescription
The sensitivity, positive predictive value, and negative predictive value.4 monthsAbnormal blood vessels or lack of staining is defined as suspected lesions. All the suspected lesions were biopsied.

Countries

China

Contacts

Primary ContactYayi He, Ph.D, MD
2250601@qq.com+8621 65115006

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026